Artelo Biosciences (ARTL) Non Operating Income (2017 - 2025)

Artelo Biosciences (ARTL) has reported Non Operating Income for 7 consecutive years, with -$1.4 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non Operating Income fell 4158.82% year-over-year to -$1.4 million in Q4 2025; TTM through Dec 2025 was -$1.5 million, a 623.05% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 million, down 623.05% from the prior year.
• Non Operating Income was -$1.4 million for Q4 2025 at Artelo Biosciences, down from -$31000.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $185000.0 in Q2 2023 and troughed at -$1.4 million in Q4 2025.
• A 5-year average of -$19333.3 and a median of $48500.0 in 2024 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income surged 752.63% in 2023 and plunged 4158.82% in 2025, its largest moves.
• Over 5 years, Non Operating Income stood at $4000.0 in 2021, then soared by 3325.0% to $137000.0 in 2022, then advanced by 21.9% to $167000.0 in 2023, then tumbled by 79.64% to $34000.0 in 2024, then sank by 4158.82% to -$1.4 million in 2025.
• The last three Non Operating Income figures came in at -$1.4 million (Q4 2025), -$31000.0 (Q3 2025), and -$71000.0 (Q2 2025), per Business Quant data.